Inspire Medical Systems, Inc. (NYSE:INSP) Stock Rated “Hold” by Wall Street Brokerages

Inspire Medical Systems, Inc. (NYSE:INSP) has been given an average rating of “Hold” by the twenty analysts that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $67.29.

Several research analysts recently issued reports on INSP shares. Stifel Nicolaus lifted their target price on Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Robert W. Baird increased their price target on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. raised their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Finally, Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Tuesday, August 4th.

Insiders Place Their Bets

In related news, insider Jason Kelly sold 963 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Inspire Medical Systems in the 2nd quarter worth approximately $296,000. WINTON GROUP Ltd increased its position in shares of Inspire Medical Systems by 790.8% during the second quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock valued at $1,669,000 after acquiring an additional 33,212 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Inspire Medical Systems during the second quarter valued at approximately $131,000. Allworth Financial LP lifted its holdings in Inspire Medical Systems by 275.7% during the second quarter. Allworth Financial LP now owns 1,980 shares of the company’s stock worth $88,000 after acquiring an additional 1,453 shares during the period. Finally, Nykredit A S bought a new stake in Inspire Medical Systems during the second quarter worth $78,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $67.38 on Thursday. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 5.16 and a beta of 0.73. The firm’s 50-day simple moving average is $64.53 and its 200 day simple moving average is $53.97.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company’s quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts predict that Inspire Medical Systems will post 1.24 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.